Periyasamy Kuppusamy, Baskaran Kuppusamy, Ilakkia Aruldass, Vanitha Kalappan, Selvaraj Sundaramoorthy, Sakthisekaran Dhanapal
Department of Medical Biochemistry, Dr. ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, 600 113, India.
Cancer Chemother Pharmacol. 2015 Feb;75(2):263-72. doi: 10.1007/s00280-014-2629-z. Epub 2014 Nov 28.
The aim of the present study was to assess the chemopreventive and chemotherapeutic efficacy of tangeretin on DMBA-induced oxidative stress in breast cancer-bearing Sprague-Dawley rats.
In this study, the experimental animals were divided into five groups of six animals each. Group I was control, Group II was DMBA-induced breast cancer-bearing rats, Group III was tangeretin pre-treated (50 mg/kg body weight for 30 days orally) breast cancer-bearing animals, Group IV was tangeretin post-treated (50 mg/kg body weight for 30 days orally) and Group V was tangeretin (50 mg/kg body weight) alone treated animals.
We have observed the general characteristics of cancer, oxidative stress markers, breast cancer marker, antioxidants and histopathological changes in the experimental animals. We have recorded the body weight, tumor weights, tumor volume and antitumor activity of tangeretin in the experimental animals. Oxidative stress markers, like NO and LPO, and breast cancer marker CEA levels were significantly (p < 0.001, p < 0.05) increased as well as the antioxidants like SOD, CAT, GPx, GST, GSH, ascorbic acid and α-tocopherol were found to be significantly (p < 0.05) decreased in cancer-bearing Group II animals. Whereas, the enzymic and non-enzymic antioxidant levels were found to be significantly decreased in cancer-bearing animals. However, in tangeretin pre-treated and post- treated animals, the levels of antioxidants and breast cancer marker were found to be significantly (p < 0.05) reduced with a concomitant increase in the activities of the antioxidants (p < 0.05). In tangeretin alone treated Group V animals, no significant changes were observed in the levels of antioxidants and breast cancer marker. These results were adequately supported by the histopathological studies in the mammary tissues of the experimental animals.
From this study, we conclude that the administration of tangeretin was found to be beneficial against DMBA-induced oxidative stress in breast cancer-bearing animals. Hence, we strongly suggest that tangeretin is effective and efficient candidate for the treatment of experimental breast cancer.
本研究旨在评估橘皮素对二甲基苯并蒽（DMBA）诱导的荷乳腺癌斯普拉格-道利大鼠氧化应激的化学预防和化疗效果。
在本研究中，实验动物被分为五组，每组六只动物。第一组为对照组，第二组为DMBA诱导的荷乳腺癌大鼠，第三组为经橘皮素预处理（口服50mg/kg体重，持续30天）的荷乳腺癌动物，第四组为经橘皮素后处理（口服50mg/kg体重，持续30天），第五组为单独给予橘皮素（50mg/kg体重）处理的动物。
我们观察了实验动物的癌症一般特征、氧化应激标志物、乳腺癌标志物、抗氧化剂以及组织病理学变化。我们记录了实验动物的体重、肿瘤重量、肿瘤体积以及橘皮素的抗肿瘤活性。在荷癌的第二组动物中，氧化应激标志物如一氧化氮（NO）和脂质过氧化物（LPO）以及乳腺癌标志物癌胚抗原（CEA）水平显著升高（p<0.001，p<0.05），同时抗氧化剂如超氧化物歧化酶（SOD）、过氧化氢酶（CAT）、谷胱甘肽过氧化物酶（GPx）、谷胱甘肽S-转移酶（GST）、谷胱甘肽（GSH）、抗坏血酸和α-生育酚显著降低（p<0.05）。然而，在经橘皮素预处理和后处理的动物中，抗氧化剂水平和乳腺癌标志物显著降低（p<0.05），同时抗氧化剂活性显著增加（p<0.05）。在单独给予橘皮素处理的第五组动物中，抗氧化剂水平和乳腺癌标志物未观察到显著变化。这些结果在实验动物乳腺组织的组织病理学研究中得到了充分支持。
从本研究中，我们得出结论，发现给予橘皮素对荷乳腺癌动物中DMBA诱导的氧化应激有益。因此，我们强烈建议橘皮素是治疗实验性乳腺癌的有效候选药物。
Zotero 插件